Compare Johnson & Johnson (JNJ) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Johnson & Johnson trades at $260.54 (market cap $626.09B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.29. The key difference: Johnson & Johnson pays a 2.06% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| JNJ | USIG | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Fixed Income |
52-Week High | $267.24 | $52.69 |
52-Week Low | $172.78 | $50.18 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
USIG is trading at $50.32, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments, with the latest being $0.21 per share. A key development is AM Best's affirmation of credit ratings for USIG subsidiaries following a transaction with Tiptree Inc., as reported by Business Wire on July 30, 2026.
The outlook is cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may arise from stable dividend payments and institutional interest, such as Bank of New York Mellon Corp increasing its stake. Risks include reliance on external financial data and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
